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Abstract
Background: The early detection of prostate cancer has resulted in an increase in the number of patients with localized
prostate cancer and has paralleled the reported reduction in prostate cancer mortality. The increased rate of detection
of patients with localized prostate cancer may also increase the risk of potentially morbid therapy in a patient with
indolent cancer. Defining the biomarker correlates of prostate cancer virulence will facilitate the appropriate application
and development of therapy for patients with early disease.
Methods: A 255 core prostate cancer tissue microarray (TMA) from 47 prostatectomy specimens with organ confined
tumor was constructed. Prostate cancer foci of transition and peripheral zone origin were represented on the TMA.
Further, replicate cores of the two Gleason grades comprising the Gleason score, representative of Gleason scores 5-
9, were arrayed from each prostatectomy specimen. Standard immunohistochemical techniques were used to assess
expression of nine, cell death and cell cycle regulatory proteins implicated in the pathogenesis of prostate cancer (bax,
bcl-2, bcl-xL, bin1, CD95, mdm2, p21, p53, and NFkB).
Results: The Spearman correlation coefficient revealed a strong correlation of bax, bin1, FAS, p65 and p21 expression
with Gleason grade. Spearman correlation coefficients showed that expression of, bax and bin1, bax and MDM2, Bax and
p21, and bax and p65 NFkB was highly associated. Other significant associations were identified between bin1 and p21,
bin1 and MDM2, bin1 and p65 NFkB and between p21 and p65 NFκB. A model for predicting the biological potential of
Gleason score 7 prostate cancer using multivariable logistic regression methods was developed. The findings also indicate
that the profile of specific markers for Gleason grade 3 prostate cancer correlates with the overall context of the Gleason
score.
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Conclusion: These data support the view that important molecular differences exist among and between the Gleason
scores. Furthermore, there is significant molecular heterogeneity among prostatectomy specimens containing Gleason
grade 3 cancer. This observation may have broader implications regarding the determination of risk among patients with
prostate cancer that is currently considered to be of either good prognosis or unclear prognosis, i.e. Gleason score 7
tumors.
Background
The prediction of outcome in prostate cancer would
immediately benefit a portion of patients diagnosed with
early stage prostate cancer detected because of the wide-
spread application of PSA screening. Patients with aggres-
sive disease would be encouraged to consider early
intervention whereas those with cancer that are not likely
to progress could safely be managed by watchful waiting.
Current strategies apply morphologic criteria to approach
this problem. The understanding of the molecular basis of
prostate cancer provides an opportunity to develop an
objective method to address these issues as well as the
potential to provide insights into the mechanistic basis of
prostate cancer progression. The dilemma of most
patients with prostate cancer is that they are increasingly
comprised of low volume Gleason score 7 tumors
detected by routine screening thus exposing some patients
to the risk of unnecessary intervention. In addition, this
heterogeneity has made it difficult to perform efficient
clinical investigation in these patients.
The development of tissue microarrays (TMA) represents
a significant technical advance and enables a much higher
throughput in the assessment of the clinical and prognos-
tic significance of candidate biomarkers [1]. TMAs have
the additional advantage of maximizing the utilization of
frequently limited tissue samples. TMA technology is also
expanding our conceptual approaches to the analysis of
routinely acquired human tissue samples. TMAs can be
designed to address specific clinical or pathologic ques-
tions of interest including tumor type, tumor progression,
and response to therapy. TMAs are frequently incorpo-
rated into global genomic expression profiling studies of
human tumors as a means to rapidly validate newly iden-
tified, and potentially informative, biomarkers [2-4].
Structured information obtained from tissue microarray
analysis is analogous to that obtained from high density
cDNA microarrays, "chips", now routinely used in expres-
sion profiling studies. Thus, as with cDNA arrays, it is pos-
sible to use the large amounts of data (routinely
thousands of data points from multiple biomarkers) to
develop statistical models appropriate to questions of
clinical and biologic interest. With these issues in mind a
255 core TMA was created, representative of tumor foci
from 47 prostatectomy specimens from patients with
organ confined prostate cancer that received no other
form of therapy. The array was constructed to address the
speculation that variation in biomarker expression could
define signatures associated with the zonal origin of
tumors. It was further speculated that biomarker signa-
tures could identify subsets of cancers within Gleason
grades as defined by histopathology and provide a basis
for more accurate prognostication. The microarray
included replicate samples of the two Gleason grades
comprising the Gleason score for each tumor focus
arrayed. A selected number of cell death and cell cycle reg-
ulatory proteins were assessed using routine immunohis-
tochemistry. Using this data, a model for predicting the
biologic potential of Gleason score 7 prostate cancer using
multivariable logistic regression methods was developed.
These findings also indicate that the profile of specific
markers for Gleason grade 3, a critical component of
Gleason score 7, prostate cancer correlates with the overall
context of the Gleason score. This suggests that the molec-
ular profile of the Gleason grade 3 component varies, and
correlates, with the overall Gleason score of the tumor
focus and challenges the concept that all Gleason grade 3
prostate cancer components are clinically and biologically
equivalent.
Methods
Tissue Acquisition and Construction of Tissue Microarray
The Beecher Instrument (Silver Spring, MD) tissue micro-
array apparatus was used to generate the TMA. An H&E
stained section from each donor block was examined and
the areas of interest identified and marked. A 10 mm thick
paraffin block was prepared to be used as the recipient
block. The corresponding H&E stained slide, or image
transparency, was placed over the donor block and the
area of interest aligned with the stylet. The sample infor-
mation (i.e. address and source of the core within the
microarray) was entered onto an array worksheet. Individ-
ual areas of the two Gleason grades comprising the
Gleason score of the tumor focus were each sampled 3
times. The completed array represented a total of 50
donor blocks from 47 prostatectomy specimens and was
comprised of 255 individual cores, each 0.6 mm in diam-
eter. Each of the 50 donor blocks was representative of a
tumor focus so that one tumor focus was arrayed for 44 of
the prostatectomies and 2 tumor foci were arrayed for 3 of
the prostatectomies. All patient samples were collected in
accordance with established practices and procedures andBMC Medical Genomics 2008, 1:1 http://www.biomedcentral.com/1755-8794/1/1
Page 3 of 9
(page number not for citation purposes)
were approved by the Internal Review Board at UT- MD
Anderson Cancer Center, Houston, TX.
Immunohistochemical Techniques
All immunohistochemical sections were stained with a
Dako Autostainer utilizing standard immunohistochemi-
cal strepavidin-biotin techniques. Sections were first
deparafinized and then rehydrated. Antigens were
retrieved using the Dako Target Retrieval solution in con-
junction with steam. Sections were then treated to block
endogenous peroxidase, avidin, biotin and protein. After
blocking, sections were incubated with specific primary
antibody at the appropriate concentration for 60 minutes
at room temperature. Primary antibodies used in this
study were bax, bcl-xL, bcl-2, bin-1, CD95 (Fas/APO-1),
MDM2, p21, p65 (NFkB), and p53 (DAKO, Calbiochem,
Santa Cruz, Alexis, R & D). The primary antibody 2F11 is
a 'pan-Bin1' antibody that recognizes all the Bin1 splice
isoforms that have been described [5]. Sections were
rinsed and then incubated with a biotinylated universal
secondary antibody followed by horseradish peroxidase
labeled strepavidin both at room temperature for 15 min-
utes each (Dako's LSAB+ kit). The 3,3 diaminobenzidine
substrate was then applied for 15 minutes at room tem-
perature. Sections were counterstained with Mayer's
hematoxylin, dehydrated, cleared and coverslipped. The
appropriate positive and negative controls were used for
each antibody.
Tissue Array Database (TAD) and Image Analysis
The BLISS Image Analysis Workstation was used to scan
H&E and immunohistochemically-stained TMA slides.
Using the Webslide server these slides were scored and
entered directly into the TAD [6,7]. Also, an Active X com-
ponent in the TAD was developed that allows the image
scanned on the BLISS system to be linked directly with the
core in the TAD. A LaCie RAID system, approximately 900
GB of redundant storage capacity, was used to store all of
the BLISS image files.
Statistical Analysis
Spearman correlation coefficients were used to assess the
association between different biomarkers' expression, or
the association between biomarker expression and
Gleason score. Due to potential association among the
multiple cores taken from the same patient tumor sample,
a linear mixed effect model was fit to assess the associa-
tion between each biomarker's expression and zone of
tumor origin. Bonferroni correction was applied to
account for multiple testings. A GEE (Generalized Estima-
tion Equations) model was fit to simultaneously assess
the predictive effects of biomarker expressions on the
probability of having poor prognosis among patients hav-
ing Gleason score > 7 or < 7. Stepwise model selection was
carried out and the final fitted model was used to compute
the predictive probabilities for Gleason score 7 tumors to
have poor prognosis.
The biomarker expression levels were categorized as 0, 1,
2, 3 and 4. A composite score was calculated for each
Gleason score/Gleason grade combination group based
on the number of cores having each biomarker expression
level. The composite scores for each Gleason score/
Gleason grade combination were then plotted against the
9 biomarkers in a "heat" map, where bright red corre-
sponding to the highest expression level and bright green
corresponding to the lowest expression level.
Results
Construction of Prostate Tissue Microarray
A 255 core tissue microarray (TMA) was constructed from
formalin-fixed and paraffin-embedded prostatectomy
specimens obtained from patients with prostate cancer as
described in the methods. The TMA was representative of
the spectrum of prostate cancer Gleason grades, ranging
from Gleason Score 5 to Gleason Score 9. A total of 50
tumor foci (one focus from 44 specimens and 2 foci from
3 specimens) including 35 of peripheral zone and 15 of
transition zone origin were included in the array. A sum-
mary of the tissue core composition of the TMA is pre-
sented in Tables 1 and 2.
Table 1: Gleason Score Distribution of TMA
Gleason Score Gleason Grade Anatomic Zone Blocks (n)
52  +  3 T Z 5
3 + 2 TZ 5
63  +  3 T Z 5
PZ 10
73  +  4 P Z 5
4 + 3 PZ 5
84  +  4 P Z 9
3 + 5 PZ 1
5 + 3 PZ 1
94  +  5 P Z 4BMC Medical Genomics 2008, 1:1 http://www.biomedcentral.com/1755-8794/1/1
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Structuring of Immunohistochemical Data
The expression of selected biomarkers associated with cell
cycle progression and/or cell death sensitivity was
assessed using routine immunohistochemical methodol-
ogies. These markers included bax, bcl-2, bcl-xL, bin-1,
CD95 (Fas/APO-1), MDM2, p21waf1/cip1, p53, and p65
(NFkB). In order to facilitate the statistical analysis of the
immunohistochemical information of the various mark-
ers the data was structured in the following manner. The
percentage of tumor exhibiting detectable levels (i.e.,
involvement) of a specific marker was scored 0 (no detect-
able staining above background), 1 (1-25% of the tumor
cells exhibiting detectable staining), 2 (25-75% of the
tumor cells exhibiting detectable staining), or 3 (> 75% of
the tumor cells exhibiting detectable staining). The inten-
sity of staining for the individual markers, if detectable,
was scored as either low (1) or high (2). Staining intensity
was assessed relative to internal positive controls, such as
basal epithelial cells or lymphocytes present on the array,
or tissue controls used to establish the appropriate anti-
body titrations. Data analysis revealed that there was no
significant difference attributable to subcellular distribu-
tion of the biomarkers assessed in this study. In order to
incorporate both the involvement and the intensity infor-
mation for each biomarker a new variable, "expression"
was generated, which was defined as the following:
Expression = 0 if involvement = 0 (intensity = 0 by defini-
tion)
= 1 if involvement = 1
= 2 if involvement = 2
= 3 if involvement = 3 and intensity = low
= 4 if involvement = 3 and intensity = high
After careful observation of the patterns shown in our
original data, a new variable, expression, was defined
(Table 3). The data set had a special feature in that the
intensity information only became relevant in defining
''expression'' when involvement = 3. When involvement =
0, 1 or 2, all cores had ''low'' intensity, except 3 cores when
involvement = 2.
Statistical Analysis and Data Modeling of Biomarkers
The prostate cancer TMA was constructed to address sev-
eral issues of both biologic and clinical interest. It was first
of interest to determine the frequency of individual
biomarker expression and to determine the extent to
which individual biomarkers correlated with the prostate
zone of tumor origin, i.e. peripheral versus transition
zone within Gleason grade 3+3 tumors (Table 4). Bcl-2
and p53 exhibited no detectable levels of expression in
this subset of Gleason grade 3+ 3 tumors and were there-
Table 3: The number of cores by involvement and intensity 
category.
Intensity
Low High
Involvement 0 1202 0
17 0 0
21 5 9 3
35 4 7 2 5 4
Table 2: Distribution of Cores by Gleason Grade on TMA
Core Gleason Grade Core Source (Gleason Score) n
2 2 + 3 15
3 + 2 15
32  +  3 15
3 + 2 15
3 + 3 45
3 + 4 15
4 + 3 15
3 + 5 3
5 + 3 3
43  +  4 15
4 + 3 15
4 + 4 54
4 + 5 12
53  +  5 3
5 + 3 3
4 + 5 12
Total Cores (n) 255BMC Medical Genomics 2008, 1:1 http://www.biomedcentral.com/1755-8794/1/1
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fore not included in Table 4. For each of the other biomar-
kers, a linear mixed effect model was fit for the biomarker
expression, using the zone of origin as a fixed effect and
patient as a random effect. The mixed model also took
into account the potential association among multiple
cores within the same subject through modeling the vari-
ance-covariance matrix of the residuals. The model sug-
gested that there was no significant difference in CD95 or
bcl-xL expression between peripheral zone and transition
zone tumors (p = 0.61 and 0.12, respectively). Among bax
(p < 0.0001), bin-1 (p = 0.005), p21 (p = 0.0008), mdm2
(p = 0.02) and p65 NFkB (p = 0.02), the model suggested
that the expressions level in transition zone was signifi-
cantly lower than that of the peripheral zone. The Bonfer-
roni method was used to adjust for multiple comparisons
(i.e., using a cutoff value of 0.05/7 = 0.007), only bax and
p21 remained to show significant differences between the
peripheral and transition zone with regards to biomarker
expression.
The Spearman's correlation coefficient was used to assess
potential significant associations between Gleason grades
and biomarker expression for each of the nine biomarkers
assessed. The array was comprised of 30 cores of grade 2
tumor, 111 cores of grade 3 tumor, 96 cores of grade 4
tumor, and 18 cores of grade 5 tumor. Using the median
biomarker expression within each subject, there was no
significant association between the level of mdm2, bcl-xL
or p53 expression and Gleason grade (p = 0.19, p = 0.27
and p = 0.75, respectively). However, all of the six remain-
ing biomarkers exhibited a significant association with
Gleason grade. This association was strongest for bax (r =
0.62, p < 0.0001) and p21 (r = 0.57, p = 0.0002) with each
marker exhibiting increasing expression with correspond-
ing increases in Gleason grade. The majority of the cores
for Fas, and p65 exhibited no detectable expression, how-
ever, when expressed these markers were associated with
higher Gleason grade (p = 0.01 and p = 0.002, respec-
tively). The "heat map" enabled a visual representation of
the variation in individual biomarker expression associ-
ated with Gleason grade (Figure 1).
The Spearman correlation coefficient was computed to
identify significant associations between pairs of biomar-
kers (Table 5). The median biomarker expression level
within each subject was used for this calculation. This
analysis demonstrated that the expression of bax and
bin1, bax and MDM2, bax and p21, and bax and p65
NFkB was highly associated. Other significant associa-
tions were identified between bin1 and p21, bin1 and
MDM2, bin1 and p65 NFkB and between p21 and p65
NFkB. Similar associations were identified when using the
mean, instead of the median biomarker expression level
within each subject to calculate the Spearman correlation
coefficient.
Univariate and multivariable logistic regression models
were used to predict the biologic potential of Gleason
score 7 (either 3 + 4 or 4 + 3) tumors using a profile of the
biomarkers included in this study. For the purposes of this
study Gleason score 5 and 6 tumors were considered clin-
ically indolent (good prognosis) and Gleason score 8 and
9 tumors were considered clinically aggressive (poor prog-
nosis). Our goal was to assess whether Gleason score 7
Table 4: The fitted linear mixed effect models for each biomarker expression within Gleason grade 3+3 tumors, where zone of origin 
(TZ vs. PZ) was fitted as a fixed effect and patient as a random effect.
Marker Variable Coefficient SE P-value
Bax Intercept 2.73 0.18 -
TZ (vs. PZ) -2.27 0.32 < 0.0001
Bcl-XL Intercept 3.58 0.15 -
TZ (vs. PZ) -0.25 0.15 0.12
Bin1 Intercept 2.13 0.25 -
TZ (vs. PZ) -1.47 0.44 0.005
FAS Intercept 0.27 0.22 -
TZ (vs. PZ) -0.20 0.39 0.61
MDM2 Intercept 2.81 0.60 -
TZ (vs. PZ) -2.81 1.04 0.02
P21 Intercept 2.67 0.28 -
TZ (vs. PZ) -2.13 0.49 0.0008
P65 Intercept 1.67 0.37 -
TZ (vs. PZ) -1.67 0.63 0.02BMC Medical Genomics 2008, 1:1 http://www.biomedcentral.com/1755-8794/1/1
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tumors are more similar to Gleason score < 7 (good prog-
nosis) tumors or closer to Gleason score > 7 (poor prog-
nosis) tumors, based on a fitted model using biomarker
expression profiles. First, a generalized estimation equa-
tion (GEE) model was fit for the patients with Gleason
score not equal to 7. The response variable was equal to 1
if the patient had poor prognosis (i.e., Gleason score > 7),
and 0 otherwise. The GEE method takes into account the
association among the multiple cores obtained from the
same patient through modeling a working correlation
matrix. In our case, the working correlation matrix was
specified to be "unstructured" (UN). After a stepwise
model selection procedure, a final fitted model was deter-
mined (Table 6). Based on this model, Bax involvement =
3, FAS involvement > 0, p21 involvement = 3 was associ-
ated with an increased odds of having poor prognosis,
Plot of biomarker expression vs. Gleason grade Figure 1
Plot of biomarker expression vs. Gleason grade. Bright red corresponds to the highest expression level, black corresponds to 
moderate expression and light green is the lowest expression.
Table 5: Spearman correlation among biomarkers with regards to the median expression levels within subject.
Bax Bcl-2 Bcl-XL Bin1 FAS MDM2 p21 p53 p65
Bax 1 0.42 0.47 0.78 0.39 0.57 0.68 0.33 0.58
Bcl-2 1 0.14 0.01 0.25 0.08 0.44 0.21 0.31
Bcl-XL 1 0.48 0.07 0.25 0.39 -0.08 0.32
Bin1 10 . 3 7 0.54 0.63 0.27 0.62
FAS 1 0.20 0.19 0.38 0.37
MDM2 1 0.38 0.38 0.49
p21 1 0.19 0.63
p53 1 0.34
p65 1BMC Medical Genomics 2008, 1:1 http://www.biomedcentral.com/1755-8794/1/1
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and Bcl-XL intensity = high was associated with a reduced
odds of having poor prognosis.
The model shown in Table 6 was used to predict the prob-
ability of having poor prognosis for the patients with
Gleason score 7 tumors (n = 10 patients). The results indi-
cate that the predicted probability of poor prognosis in
those Gleason score 7 patients (i.e., the within-patient
mean predicted probability) ranges from 0.340 to 0.467.
In contrast, in patients with Gleason score greater than 7,
the predicted probability for poor prognosis ranges from
0.386 to 0.417, while in patients with Gleason score less
than 7, the predicted probability ranges from 0.312 to
0.376, except for one patient whose predictive probability
is 0.426. If 0.386 is used as the cutoff value for classifying
poor prognosis, then 6 out of the 10 patients with
Gleason score 7 would be classified as having poor prog-
nosis.
Subsequently, it was of interest to determine whether all
Gleason grade 3 tumor areas were equivalent with respect
to the biomarker expression profile, or whether subsets
could be defined which exhibited differences in biomar-
ker expression. The Gleason scores containing '3' include
2+3, 3+2, 3+3, 3+4, 4+3, 3+5 and 5+3. The association
between Gleason score and biomarker expression was
assessed using the Spearman correlation coefficient.
Again, the median biomarker expression was used in each
patient. This analysis revealed significant differences
between Gleason grade 3 biomarker signatures that varied
within the context of the Gleason score (Table 7). This
finding implies that, with respect to the expression of the
biomarkers assessed in this study, not all Gleason grade 3
tumor areas are equivalent. Further, the results indicate
that the Gleason grade 3 signatures obtained correlated
with the corresponding clinically indolent or clinically
aggressive categories of the overall Gleason score.
Discussion
The use of TMAs as a strategy to validate and characterize
candidate biomarkers is gaining widespread acceptance as
an alternative to more traditional immunohistochemical
methods. Less widely appreciated, is that TMAs also facil-
itate a rapid assessment of biomarker expression in larger
cohorts of tissue and are thereby amenable to the develop-
ment of statistical models based on structured immuno-
histochemistry information [8]. In this regard it is
noteworthy that while there is general acknowledgement
of the prognostic value of the Gleason score there is also
agreement on the limitations of morphology in the pre-
diction of clinical outcome for individual patients. In part
this limitation may be attributable to the considerable
interobserver variability in the assignment of Gleason
grade [9].
In this study, a 255 core TMA comprising the spectrum of
low grade to high grade Gleason scores of organ confined
tumors was used to address several questions of clinical
and pathological interest based on statistical modeling of
the expression of selected biomarkers. These biomarkers
were comprised of well characterized cell cycle (p53, p21,
mdm2) and cell death (p53, bax, bcl-xL, bcl-2, bin1,
CD95, NFkB) regulators variably expressed by human
prostate cancers [5,10-16]. Available evidence suggests
that at least several of these proteins may be of predictive
value [15,17-21]. While the scope of this study is focused
on a small number of selected biomarkers, the analysis is
based on nearly 7,000 data elements and highlights the
critical issues of data management and distribution. A tis-
sue array database (TAD) was, therefore, developed to
facilitate the structuring, storage, and distribution of
biomarker information. TAD consists of an Active Server
Page web interfaced with a relational database that auto-
mates recording biomarker scores and links the structured
data with clinical and pathologic information. TAD is an
open source application that can be installed locally.
It is widely appreciated that Gleason score 7 prostate can-
cers in aggregate have an intermediate prognosis but are
clinically heterogeneous despite their morphologic simi-
larities and, conversely, a significant number of Gleason
score 6 prostate cancers, despite their overall good prog-
nosis, exhibit clinically aggressive behavior [22]. Clearly,
a biomarker signature capable of contributing to the pre-
dictive value of accepted histopathologic information
would be of considerable value. As a first step to realizing
this goal we modeled expression of selected proteins on a
tissue microarray comprising the spectrum of Gleason
score organ confined tumors. Our analysis suggests that
four markers (bcl-xL, Fas, bax, and p21) provided poten-
Table 6: Fitted GEE model for predicting poor prognosis (GS > 7) in patients with Gleason score < 7 or > 7.
Effect Coefficient Standard Error 95% Confidence Limits P-value
Intercept 0.32 0.07 - - -
Bax involvement = 3 0.04 0.02 0.002 0.08 0.04
FAS involvement = 1, 2 or 3 0.05 0.02 0.02 0.08 0.001
p21 involvement = 3 0.05 0.01 0.03 0.07 < .0001
Bcl-xl intensity = high -0.05 0.02 -0.08 -0.01 0.01BMC Medical Genomics 2008, 1:1 http://www.biomedcentral.com/1755-8794/1/1
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tially important information predictive of clinically
aggressive behavior. The findings also indicate, that
tumors of equivalent Gleason grade although morpholog-
ically similar, have varying patterns of biomarker expres-
sion that correlate with the Gleason score of the tumor.
Represented in the TMA were 15 cases of Gleason score 6
(3 + 3) carcinoma consisting of tumors of transition zone
(5 cases) or peripheral zone (10 cases) origin defined by
established histopathological criteria, that enabled an
assessment of the potential variability of individual
biomarker expression as a function of zonal origin of the
tumor. Tumors of peripheral zone origin that exhibited
secondary involvement were excluded. It is noteworthy
that bax, bin1, mdm2, p21, and p65 NFkB were all
expressed at significantly higher levels in peripheral zone
tumors compared to transition zone tumors of equivalent
Gleason score. Although establishing the biological, or
potential clinical, significance of these observations is
beyond the scope of the current study it is of interest that
transition zone prostate carcinomas are both less com-
mon and typically indolent compared to their counter-
parts arising from the peripheral zone [23,24].
Additionally, it has been speculated that transition zone
and peripheral zone carcinoma may arise from different
precursor lesions [23]. Although it has not been previ-
ously established, it is, therefore, not completely unantic-
ipated that carcinomas arising from the peripheral zone
would exhibit patterns of biomarker expression that differ
from those arising in the transition zone.
In pairwise comparisons of the expression of the nine
biomarkers using Spearman correlation coefficients sev-
eral combinations of biomarkers exhibited highly con-
cordant expression. There were significant associations
between bcl-xL and bax, bax and bin1, and bax and p21.
Although proapoptotic and antiapoptotic proteins of the
bcl-2 gene family have been shown to be coordinately reg-
ulated [25], as well as bax and p21 [26], an association
between bax and bin1 has not been described. It would be
of interest to determine the extent to which apoptosis, or
tumor suppressor activity, mediated by bin1 may be
dependent on bax.
The results of this study suggest opportunities for future
laboratory-based mechanistic studies. Finally, biostatisti-
cal strategies are presented that suggest it may be possible
to use a panel of biomarkers to provide predictive infor-
mation about Gleason score 7 prostate cancers. Ulti-
mately, these findings will need to be expanded to
determine, prospectively, whether they will prove of clin-
ical utility beyond current histopathologic variables
including Gleason grade and tumor stage. It is anticipated
that multiparametric analyses can be performed on lim-
ited tumor specimens and will lead to improved clinical
investigation and better validation of mechanistic con-
cepts. Incremental advances in prostate cancer therapy
will likely rely on integration of validated molecular infor-
mation with the widely applied morphologic characteri-
zation of prostate cancer. Integration of this information
with other prognostic variables including tumor stage and
pretreatment PSA levels will be necessary to establish its
ultimate utility. This will necessitate rigorous validation in
clinically annotated specimens with long-term follow up.
Conclusion
In general improved models of prediction of disease out-
come are required to allow the clinician to design more
appropriate treatment modalities for prostate cancer
patients. This study presents data supporting the theory
that significant differences in molecular signatures exist
among a large group of Gleason grade 3 cancers. Further-
more, a biostatistical model was developed using a lim-
ited number of molecular markers that may enable more
accurate prediction of risk of prostate cancer progression.
These findings support a more detailed study of a larger
cohort of clinically annotated tissue from prostate cancer
patients.
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